Seattle, WA Clinical Trials Report — April 2026

For Seattle residents considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across Seattle, 74 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and cardiovascular health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer AJCC V8 (2 trials)
• Leukemia (2 trials)
• Hematopoietic and lymphatic system neoplasm (2 trials)
• Multiple myeloma (2 trials)
• Anatomic stage II breast cancer AJCC V8 (2 trials)
• Alzheimer disease (2 trials)
• Anatomic stage III breast cancer AJCC V8 (2 trials)
• Heart failure (2 trials)
• Advanced solid tumors (1 trial)
• Amputation (1 trial)

This month, Seattle saw the opening of 11 new clinical trials, matching the 11 trials that launched in March 2026. This consistent pace indicates a steady flow of new research opportunities. Overall, Seattle remains a robust center for medical research, with a total of 1,248 clinical trials currently recruiting across 345 research facilities.

Spotlight on New Research Opportunities

April brings several notable new trials to Seattle, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Boehringer Ingelheim is initiating NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer and aims to determine if obrixtamig plus standard chemotherapy improves survival compared to standard chemotherapy alone, involving 390 participants.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )." This Phase 3, randomized, double-blinded, placebo-controlled study will evaluate CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Seattle Children's Hospital is sponsoring NCT07522112, "Evaluating a Shared Decision-making Intervention for Families About Firearm Storage." This trial, aiming for 548 participants, will assess the effectiveness of the Family Safety Check-In website on firearm storage practices.
• The Seattle Institute for Biomedical and Clinical Research is leading NCT07507435, "Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults." This study, designed for 480 participants, addresses the elevated risk of community-acquired pneumonia in people with HIV.

New trials this month are exploring a range of conditions, including hematopoietic and lymphatic system neoplasm, chronic graft versus host disease, HIV, inhaled corticosteroid use, malignant solid neoplasm, Parkinson disease, pneumonia, proton pump inhibitor use, and safety studies. Drug trials account for 5 of the new studies, followed by 2 device trials, 2 other types of studies, and 2 procedure-based trials, alongside 1 behavioral and 1 biological trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research. 3 of the new trials launched this month are actively seeking healthy volunteers. Across Seattle, a total of 117 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements, including the 9 trials closing soon.

Seattle's Research Powerhouses

Seattle is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Washington (183 trials)
• Seattle Children's Hospital (172 trials)
• Fred Hutchinson Cancer Center (135 trials)
• Fred Hutch/University of Washington Cancer Consortium (84 trials)
• Swedish Medical Center-First Hill (66 trials)
• University of Washington Medical Center (51 trials)
• Swedish Cancer Institute (51 trials)

Other significant contributors include University of Washington Medical Center - Montlake (44 trials), Swedish Medical Center (43 trials), Swedish Medical Center-Ballard Campus (37 trials), Swedish Medical Center-Cherry Hill (35 trials), and Fred Hutchinson Cancer Research Center (35 trials). These institutions offer a broad spectrum of research, from oncology at Fred Hutchinson Cancer Center and Swedish Cancer Institute, to pediatric research at Seattle Children's Hospital, and diverse medical fields across the University of Washington and Swedish Medical Center networks.

Expanding Your Search: Beyond Seattle

While Seattle offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Washington State. Cities with active trials include Bellevue (1 trial), Renton (1 trial), Spokane (1 trial), and Vancouver (1 trial). Exploring these nearby locations can broaden the scope of available research opportunities.

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 11 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials are specifically designed to include children, and 1 new trial is male-only. Academic institutions continue to play a vital role in Seattle's research ecosystem, with Fred Hutchinson Cancer Center and Seattle Children's Hospital sponsoring a significant portion of new trials. Industry sponsors like Incyte Corporation, Boehringer Ingelheim, and Caliway Biopharmaceuticals Co., Ltd. are also driving significant research efforts.

As we move further into spring, Seattle's research community continues to drive medical innovation, with a focus on both urgent enrollment for closing studies and the launch of new, impactful trials across a wide range of health conditions.